VIDEO ACCESS


RELEASE: October 10, 2018
EXPIRATION: December 31, 2019 (Credit is not available after this expiration date.)


LEARNING OBJECTIVES

  • Review genetic bases of immune evasion, including alterations of PD-1 ligands, in lymphoid malignancies
  • Identify associated approaches to immunomodulation in lymphoid malignancies
  • Describe newly defined genetic subsets of diffuse large B-cell lymphoma and associated clinical implications
     

Accreditation Statement

https://ce.mayo.edu/sites/default/files/CPD-JointAccreditationLogo%20%282%29_0.png


In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s)

AMA

The Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


INSTRUCTIONS

  • Click the Take Course button below.
  • Participate in the quiz. Participants must pass by a minimum of 80%, 1 re-take is allowed. Quizzes have between 2-5 questions.
  • Complete the evaluation.


TRANSCRIPT
This credit will appear on your Transcript for permanent record. To access your transcript, visit My Account, My Activities, RSS Transcript.

DISCLOSURE SUMMARY
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry:

Aaron Mansfield, M.D.                  Genentech Advisory Board                       Honoraria
John Kisiel, M.D.                           Exact Sciences, Madison, WI                   Intellectual Property
Karna Sundsted                            ACP – MKSAP 18 Writing Committee      Consultant

No relevant financial relationship(s) with industry:

John Bundrick, M.D.
Christina Dilaveri, M.D.
Lucinda Gruber, M.D.
Meltiady Issa, M.D.
Colin West, M.D., Ph.D.
Amy Williams, M.D.
RaeAnne Boldt

Speaker:
Margaret A. Shipp,  M.D.


Relevant Relationships: Grant/Research Support - Bristol Myers Squibb, Merck; Honoraria - Bristol Myers Squibb
Off Label/Investigational Usage: PD-1 blocking antibodies (nivolumab and pembrolizumab) - manufacturerr: BMS and Merck, Off-Label Use: in the context of clinical trials in specific lymphoid malignancies


QUESTIONS?
MAYO STAFF: Contact RaeAnne Boldt at 3-1846.
MAYO CLINIC CARE NETWORK MEMBERS: Contact cme@mayo.edu 
 

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here to review disclosures.

Presenter: 
Margaret A. Shipp, M.D.
Where did the idea for the course originate?: 
Minnesota
Please login or register to take this course.
Where did the idea for the course originate?: 
Minnesota